Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: hyprolose; crospovidone; hydrogenated castor oil; sodium lauryl sulfate; magnesium stearate; microcrystalline cellulose; hypromellose; dibasic sodium phosphate; colloidal anhydrous silica - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; crospovidone; hyprolose; microcrystalline cellulose; hydrogenated castor oil; hypromellose; dibasic sodium phosphate; magnesium stearate; sodium lauryl sulfate - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; sodium lauryl sulfate; hydrogenated castor oil; hyprolose; dibasic sodium phosphate; colloidal anhydrous silica; hypromellose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: hydrogenated castor oil; crospovidone; dibasic sodium phosphate; microcrystalline cellulose; hyprolose; sodium lauryl sulfate; magnesium stearate; hypromellose; colloidal anhydrous silica - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; dibasic sodium phosphate; crospovidone; colloidal anhydrous silica; hypromellose; hydrogenated castor oil; sodium lauryl sulfate - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: hydrogenated castor oil; sodium lauryl sulfate; hyprolose; microcrystalline cellulose; hypromellose; dibasic sodium phosphate; magnesium stearate; colloidal anhydrous silica; crospovidone - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; hydrogenated castor oil; hypromellose; crospovidone; magnesium stearate; sodium lauryl sulfate; dibasic sodium phosphate; microcrystalline cellulose; hyprolose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: dibasic sodium phosphate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; hydrogenated castor oil; sodium lauryl sulfate; hyprolose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: sodium lauryl sulfate; crospovidone; hypromellose; microcrystalline cellulose; hydrogenated castor oil; dibasic sodium phosphate; magnesium stearate; hyprolose; colloidal anhydrous silica - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; hydrogenated castor oil; magnesium stearate; hyprolose; crospovidone; dibasic sodium phosphate; colloidal anhydrous silica; hypromellose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.